好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Re-weighting MDS-UPDRS Motor Items for Optimal Sensitivity to Parkinson’s Disease Progression in Untreated Patients Using Parkinson’s Progression Markers Initiative Data
Movement Disorders
S2 - Movement Disorders: Epidemiology and Clinical Aspects (1:36 PM-1:48 PM)
004
Examine composite scores (CS) of re-weighted combinations the MDS-UPDRS items as a more sensitive measure of meaningful changes in motor progression.
As a complex degenerative disease, Parkinson’s disease (PD) affects motor abilities across diverse domains, even prior to initiation of dopaminergic therapy (DT). This work demonstrates how CS consisting of re-weighted combinations of the items from MDS-UPDRS Parts II and III can better detect meaningful changes in motor progression.

This study analyzed the Parkinson’s Progression Markers Initiative MDS-UPDRS data Parts II and III in subjects with confirmed PD naïve to DT. Patients were censored from the analysis once DT was initiated. The sensitivity of individual items to disease progression was assessed using partial least square regression. Selected items were weighted using the model coefficients and summed to create the CS. CS responsiveness to change was assessed using a 1-year mean-to-standard-deviation ratio (MSDR).

CS were generated for untreated subjects (n=428) across items from Parts II and III individually, and as a combined motor composite score (MCS). The three most responsive items (with their combined weights) were: turning in bed, getting out of bed/car/chair, and tremor (45%) for Part II, and leg agility (left) and rest tremor amplitude – left and right (34%) for Part III. The MSDRs increased from 0.5431 to 0.5647, and 0.6341 to 0.7040, which increases power 3% and 8%, respectively.   Items from Part II and III contributed to 37.4% and 62.6% of the weighed MCS. Similar items were retained in the MCS as in the individual CSs, and the MSDR increased from 0.7615 to 0.8591, increasing power 8%.

Endpoints derived from the CS reflecting items from combined domains can measure clinically meaningful progression of motor symptoms and the impacts with greater sensitivity compared to using the totality of items from existing tools.
Authors/Disclosures
Gilbert J. L'Italien
PRESENTER
Gilbert J. L'Italien has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Gilbert J. L'Italien has stock in biohaven pharmaceuticals.
Samuel Dickson (Pentara) No disclosure on file
Basia Rogula Basia Rogula has received personal compensation for serving as an employee of Broadstreet HEOR.
Jordan S. Dubow, MD Dr. Dubow has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Revalesio .
Nick Kozauer (Biohaven Pharmaceuticals) Dr. Kozauer has received personal compensation for serving as an employee of Biohaven. Dr. Kozauer has stock in Biohaven.
Lauren Powell (Broadstreet HEOR) Lauren Powell has nothing to disclose.
Michele Potashman, PhD (Biohaven) Dr. Potashman has received personal compensation for serving as an employee of Biohaven Pharmaceuticals.
Kim Crimin No disclosure on file
Patrick O'Keefe (Pentara) Patrick O'Keefe has received personal compensation for serving as an employee of Pentara.
Ellen Korol (Broadstreet HEOR) Ellen Korol has received personal compensation for serving as an employee of Broadstreet HEOR.
Madeleine Crabtree (Broadstreet HEOR) Madeleine Crabtree has nothing to disclose.
Fernanda Nagase (Broadstreet HEOR) Fernanda Nagase has nothing to disclose.
Vladimir Coric Vladimir Coric has received personal compensation for serving as an employee of Biohaven. Vladimir Coric has received personal compensation in the range of $1,000,000+ for serving as an officer or member of the Board of Directors for Bioahven. Vladimir Coric has stock in Biohaven. Vladimir Coric has received intellectual property interests from a discovery or technology relating to health care.
Suzanne Hendrix, PhD Dr. Hendrix has received personal compensation for serving as an employee of Pentara Corporation. Dr. Hendrix has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pentara Corporation. Dr. Hendrix has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Pentara Corporation. The institution of Dr. Hendrix has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Pentara Corporation. Dr. Hendrix has stock in Pentara.